Condition: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma · Sponsor: Antengene Biologics Limited
This is A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This description comes directly from the study's public registry record.
Tingting Yu · 021-32501095 · tingting.yu@antengene.com
Sunny He · 13810001510 · sunny.he@antengene.com
Always discuss trial participation with your own doctor first.
| Anhui Provincial Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| The First Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | Not Yet Recruiting |
| Beijing Cancer hospital | Beijing, Beijing Municipality, China | Recruiting |
| Fujian Provincial Cnacer Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Not Yet Recruiting |
| Gansu Provincial Cnacer Hospital | Lanzhou, Gansu, China | Not Yet Recruiting |
| Cancer Institute&Hospital Chinese Academy of Medical Sciences | Langfang, Hebei, China | Not Yet Recruiting |
| The Fourth Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | Not Yet Recruiting |
| Anyang Tumor Hospital | Anyang, Henan, China | Not Yet Recruiting |
| The First Affiliated Hospital of Henan Medical Hospital | Xinxiang, Henan, China | Not Yet Recruiting |
| Henan Cnacer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| The First Affiliated Hospital of Zhenghzou University | Zhengzhou, Henan, China | Not Yet Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07327229